Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Fuji
Queensland Health
Julphar
Express Scripts
Argus Health
Farmers Insurance
US Army
Harvard Business School

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DORZOLAMIDE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Dorzolamide Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00108017 Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 This study is comparing 2 medications for glaucoma and how effective they are at controlling glaucoma over the course of an entire day.
NCT00140049 A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma Completed Pfizer Phase 4 To demonstrate the statistical non inferiority of the combination of latanoprost and timolol given in the evening time once a day vs the combination of dorzamalide and timolol twice a day based on intraocular pressure measurements at 8 AM, 12 noon & 4 PM during a 12 week treatment.
NCT00152932 Ocular Blood Flow in Early Glaucoma Patients Before and After Treatment With Dorzolamide Unknown status Merck Frosst Canada Ltd. N/A Impaired ocular blood flow is an important risk factor in the pathogenesis of primary open angle glaucoma (POAG). A few studies suggest that topical dorzolamide 2% may increase optic nerve perfusion. The objectives of this study are to learn the effects of dorzolamide on the retinal and optic nerve blood flow of glaucoma patients. The present study is a prospective, randomized, double-masked, crossover design study of newly diagnosed or already treated patients with early glaucoma. The investigators will check ocular blood flow parameters using the Canon Laser Blood Flowmeter (CLBF), used to evaluate retinal arteriole blood flow, and the Heidelberg retinal flowmeter (HRF), which measures blood flow through capillary beds in the retina and optic nerve head. Any demonstrated improvements to retinal and optic nerve blood flow with dorzolamide, will mean that the drug may protect against ischaemic nerve and retinal damage. Any documented improvement in flow could lead to a major change in the management of glaucoma patients as well as other retinal ischemic diseases such as diabetic retinopathy and central retinal vein occlusion.
NCT00152932 Ocular Blood Flow in Early Glaucoma Patients Before and After Treatment With Dorzolamide Unknown status University Health Network, Toronto N/A Impaired ocular blood flow is an important risk factor in the pathogenesis of primary open angle glaucoma (POAG). A few studies suggest that topical dorzolamide 2% may increase optic nerve perfusion. The objectives of this study are to learn the effects of dorzolamide on the retinal and optic nerve blood flow of glaucoma patients. The present study is a prospective, randomized, double-masked, crossover design study of newly diagnosed or already treated patients with early glaucoma. The investigators will check ocular blood flow parameters using the Canon Laser Blood Flowmeter (CLBF), used to evaluate retinal arteriole blood flow, and the Heidelberg retinal flowmeter (HRF), which measures blood flow through capillary beds in the retina and optic nerve head. Any demonstrated improvements to retinal and optic nerve blood flow with dorzolamide, will mean that the drug may protect against ischaemic nerve and retinal damage. Any documented improvement in flow could lead to a major change in the management of glaucoma patients as well as other retinal ischemic diseases such as diabetic retinopathy and central retinal vein occlusion.
NCT00273429 Cosopt Versus Xalatan Completed Pharmaceutical Research Network Phase 4 To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.
NCT00273442 Assessing Cosopt Switch Patients Completed Pharmaceutical Research Network Phase 4 To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.
NCT00273455 Lumigan Versus Cosopt Completed Pharmaceutical Research Network Phase 4 To compare the intraocular pressure effect and safety of the dorzolamide/timolol fixed combination given twice daily versus bimatoprost given once every evening in patients with open-angle glaucoma in patients insufficiently controlled on latanoprost monotherapy
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Dorzolamide Hydrochloride

Condition Name

Condition Name for Dorzolamide Hydrochloride
Intervention Trials
Ocular Hypertension 22
Glaucoma 20
Open-angle Glaucoma 9
Primary Open Angle Glaucoma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Dorzolamide Hydrochloride
Intervention Trials
Glaucoma 35
Ocular Hypertension 23
Glaucoma, Open-Angle 20
Hypertension 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Dorzolamide Hydrochloride

Trials by Country

Trials by Country for Dorzolamide Hydrochloride
Location Trials
United States 29
Greece 5
Italy 4
Canada 3
Singapore 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Dorzolamide Hydrochloride
Location Trials
Pennsylvania 5
Illinois 4
Florida 3
Massachusetts 2
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Dorzolamide Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Dorzolamide Hydrochloride
Clinical Trial Phase Trials
Phase 4 21
Phase 3 10
Phase 2/Phase 3 2
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Dorzolamide Hydrochloride
Clinical Trial Phase Trials
Completed 34
Unknown status 7
Recruiting 5
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Dorzolamide Hydrochloride

Sponsor Name

Sponsor Name for Dorzolamide Hydrochloride
Sponsor Trials
Merck Sharp & Dohme Corp. 6
Allergan 4
Alcon Research 3
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Dorzolamide Hydrochloride
Sponsor Trials
Other 38
Industry 24
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Fuji
Johnson and Johnson
QuintilesIMS
Baxter
Queensland Health
Federal Trade Commission
Cipla
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.